Search

everythinglearnresearchcommunity

for

Search:↓

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

The user reports significant hair regrowth using a topical solution of 5% minoxidil and 0.1% finasteride twice daily, along with derma rolling twice a week. They have not experienced shedding and are optimistic about continued hair growth.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The user updated their hair loss treatment to include daily dutasteride, oral minoxidil, topical dutasteride with minoxidil and tretinoin, and RU58841. Commenters feel the extensive treatment is unnecessary for the user's level of hair loss.

The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.

Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.

Mixing RU58841 with minoxidil compounded with tretinoin is discussed, with concerns about systemic absorption. Topical dutasteride and finasteride are also mentioned as treatments, with varying personal experiences and concerns about side effects.

The conversation discusses using RU58841, Minoxidil, and finasteride for hair loss treatment. It focuses on homebrewing RU58841 while using other treatments.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

User shared 1-year progress of hair growth using Fin, Min, Micro, Alfatradiol, and vitamins. Photos show improved hairline and increased grays.

The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.

The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

Dermastamp is preferred for hair growth and skin health due to fewer scars, with recommended needle sizes of 0.5-1.5mm. Dermapen is also favored over dermarollers, which are considered dangerous.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

Transgender hormone therapy, including Estradiol Valerate, Spironolactone, and Progesterone Micronized, can reverse male pattern baldness and improve hair health. The user shares their positive experience with hair regrowth after transitioning from male to female.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.

A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.